Long-Acting Injectables (LAIs) Market Report 2026

Long-Acting Injectables (LAIs) Market Overview

• Long-Acting Injectables (LAIs) market size has reached to $13.31 billion in 2025 • Expected to grow to $24.45 billion in 2030 at a compound annual growth rate (CAGR) of 13% • Growth Driver: The Increasing Burden Of Schizophrenia Driving The Growth Of The Market Due To Improved Mental Health Awareness • Market Trend: Advanced Sustained-Release Depot Platforms Enable Longer Dosing Intervals And Improved Patient Adherence In Injectable Therapies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Long-Acting Injectables (LAIs) Market?

Long-acting injectables (LAIs) refers to a class of medications that are formulated to be released slowly into the body over an extended period after a single injection. This delivery system maintains stable drug levels in the bloodstream for weeks or months, reducing the need for frequent dosing compared to traditional oral or short-acting injectable treatments. The main product types of long-acting injectables (LAIs) include antipsychotic long acting injectables, hormonal long acting injectables, antiviral long acting injectables, pain management long acting injectables, and other product types. Antipsychotic long acting injectables refer to extended-release injectable formulations designed to provide sustained therapeutic effects and improve treatment adherence. These products are based on technologies including microsphere based formulations, polymer based depot systems, nano formulations, liposomal delivery systems, and in situ forming depots and are administered through intramuscular, subcutaneous, and other route of administrations. The key applications of schizophrenia, bipolar disorder, human immunodeficiency virus treatment, hormonal disorders, diabetes management, and oncology supportive care, while the end-users includes hospitals, specialty clinics, ambulatory surgical centers, homecare settings, and specialty pharmacies.

What Is The Long-Acting Injectables (LAIs) Market Growth Forecast?

The long-acting injectables (LAIs) market size is expected to see rapid growth in the next few years. It will grow to $24.45 billion in 2030 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period can be attributed to advancements in nano and polymer based drug delivery systems, increasing approvals of long-acting antiviral therapies, rising adoption of precision medicine approaches, expansion of homecare and outpatient treatment models, growing investment in extended-release injectable drug pipelines. Major trends in the forecast period include rising adoption of long-acting injectable therapies for chronic psychiatric disorder management, increasing use of depot formulations to improve patient adherence and reduce dosing frequency, growing development of advanced polymer and nano-based drug delivery systems for sustained release, expanding clinical adoption of long-acting antivirals for infectious disease management, increasing integration of long-acting injectables in outpatient and specialty clinic treatment models.

Global Long-Acting Injectables (LAIs) Market Segmentation

1) By Product Type: Antipsychotic Long Acting Injectables, Hormonal Long Acting Injectables, Antiviral Long Acting Injectables, Pain Management Long Acting Injectables, Other Product Types 2) By Technology: Microsphere Based Formulations, Polymer Based Depot Systems, Nano Formulations, Liposomal Delivery Systems, In Situ Forming Depots 3) By Route Of Administration: Intramuscular, Subcutaneous, Other Routes Of Administration 4) By Application: Schizophrenia, Bipolar Disorder, Human Immunodeficiency Virus Treatment, Hormonal Disorders, Diabetes Management, Oncology Supportive Care 5) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Homecare Settings, Specialty Pharmacies Subsegments: 1) By Antipsychotic Long Acting Injectables: Risperidone Long Acting Injection, Paliperidone Palmitate Injection, Aripiprazole Extended Release Injection, Olanzapine Long Acting Injection, Fluphenazine Decanoate Injection, Haloperidol Decanoate Injection 2) By Hormonal Long Acting Injectables: Depot Medroxyprogesterone Acetate Injection, Leuprolide Acetate Injection, Goserelin Acetate Implant Injection, Norethisterone Enanthate Injection, Estradiol Valerate Injection 3) By Antiviral Long Acting Injectables: Cabotegravir Extended Release Injection, Rilpivirine Long Acting Injection, Lenacapavir Subcutaneous Injection, Interferon Alpha Long Acting Injection 4) By Pain Management Long Acting Injectables: Bupivacaine Extended Release Injection, Morphine Depot Injection, Buprenorphine Extended Release Injection, Fentanyl Depot Injection, Methadone Long Acting Injection 5) By Other Product Types: Oncology Long Acting Injectables, Anti Infective Long Acting Injectables, Immunotherapy Long Acting Injectables, Vaccination Depot Formulations, Metabolic Disorder Long Acting Injectables

What Is The Driver Of The Long-Acting Injectables (LAIs) Market?

The increasing burden of schizophrenia is expected to propel the growth of the long-acting injectables (LAIs) market going forward. Schizophrenia is a chronic mental health disorder that affects a person’s thinking, emotions, and behavior, often causing hallucinations, delusions, and disorganized thinking. The increasing burden of schizophrenia is due to improved mental health awareness, which leads to more people recognizing symptoms and seeking diagnosis. Long-acting injectables (LAIs) help in schizophrenia by ensuring consistent medication delivery over time, which improves treatment adherence, reduces relapse risk, and supports better long-term symptom control. For instance, in January 2026, according to WebMD LLC, a US-based online digital health platform, schizophrenia imposed an economic burden of nearly $367 billion in the United States in 2024, affecting about 3.1 million adults. Therefore, the increasing burden of schizophrenia is driving the growth of the long-acting injectables (LAIs) industry.

Key Players In The Global Long-Acting Injectables (LAIs) Market

Major companies operating in the long-acting injectables (lais) market are Johnson And Johnson, Roche Holding AG, Pfizer Inc., Merck & Co. Inc., AbbVie Inc., AstraZeneca plc, Sanofi S.A., Novartis AG, Novo Nordisk A/S, GSK plc, Eli Lilly and Company, Bayer AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Shionogi And Co Ltd., Dr. Reddy’s Laboratories Ltd., ViiV Healthcare, H. Lundbeck A/S, Lupin Limited, Amneal Pharmaceuticals Inc., Alkermes plc, Syngene International Limited

Global Long-Acting Injectables (LAIs) Market Trends and Insights

Major companies operating in the long-acting injectables (LAIs) market are focusing on developing innovative solutions, such as advanced sustained-release depot formulation platforms, to enable longer dosing intervals, improve patient adherence, and enhance therapeutic consistency. Advanced sustained-release depot formulation platforms are drug delivery systems that store medication in a long-acting injectable form at the injection site and release it slowly and steadily into the body over an extended period to maintain consistent therapeutic levels. For instance, in November 2025, Lupin Limited, an India-based pharmaceutical company, launched risperidone long-acting injectable under its proprietary precisionsphere platform, designed to provide extended drug release and improved dosing convenience with CGT exclusivity in the United States. The platform incorporates advanced polymer-based delivery technology that enables sustained release of the active ingredient over an extended duration, supports better patient compliance, and reduces relapse risk by maintaining stable therapeutic levels, marking a strategic advancement in long-acting injectable therapies for neuropsychiatric conditions.

What Are Latest Mergers And Acquisitions In The Long-Acting Injectables (LAIs) Market?

In November 2023, Teva Pharmaceutical Industries Ltd., an Israel-based biopharmaceutical company, entered into a collaboration with Royalty Pharma to accelerate the development of its olanzapine long-acting injectable (LAI) program (TEV-749) for schizophrenia treatment. This partnership aims to support late-stage clinical development of the LAI formulation by providing non-dilutive funding in exchange for future royalties, thereby reducing financial risk and speeding up time-to-market for the long-acting injectable therapy designed to improve patient adherence through sustained drug release. Royalty Pharma Plc is a US-based biopharmaceutical royalty and investment company specializing in funding innovative drug development programs in exchange for future royalty-based returns.

Regional Outlook

North America was the largest region in the long-acting injectables (LAIs) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Long-Acting Injectables (LAIs) Market?

The long-acting injectables (LAIs) market consists of sales of paliperidone palmitate, risperidone microspheres, aripiprazole monohydrate, olanzapine pamoate, and naltrexone extended-release injectable. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Long-Acting Injectables (LAIs) Market Report 2026?

The long-acting injectables (LAIs) market research report is one of a series of new reports from The Business Research Company that provides long-acting injectables (LAIs) market statistics, including long-acting injectables (LAIs) industry global market size, regional shares, competitors with a long-acting injectables (LAIs) market share, detailed long-acting injectables (LAIs) market segments, market trends and opportunities, and any further data you may need to thrive in the long-acting injectables (LAIs) industry. This long-acting injectables (LAIs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.